Sandoz Announces MAA Filing for Biosimilar Pegfilgrastim

Today, Sandoz announced that the EMA has accepted its Marketing Authorization Application for its biosimlar to Amgen’s Neulasta, used to prevent infection in patients with compromised immune systems due to chemotherapy.  Sandoz’s application is supported by three pivotal clinical trials.

Download PDF